Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
HSR waiting period expires for MorphoSys–Constellation transaction
MorphoSys announced that the waiting period under the Hart-Scott-Rodino Act had expired for its tender offer for Constellation Pharmaceuticals.
2021
MorphoSys appoints Sung Lee as CFO
MorphoSys announced Sung Lee's appointment as Chief Financial Officer, effective February 2, 2021. He will succeed Jens Holstein.
2020
FDA approves Monjuvi with lenalidomide for certain DLBCL patients
MorphoSys and Incyte announced that the FDA approved Monjuvi (tafasitamab-cxix) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. The approval was under the accelerated approval program.
2019
MorphoSys reports third-quarter 2019 financial results
MorphoSys reported its third-quarter 2019 financial results, including group revenues of EUR 12.5 million and a consolidated net loss of EUR 24.2 million.